# Humira

AbbVie’s $11 Billion Gambit: Securing the Future of Immunology Beyond the Humira Cliff

AbbVie has entered an agreement to acquire Apogee Therapeutics for $10.9 billion to bolster its immunology portfolio. The deal focuses on zumilokibart, a next-generation treatment for inflammatory diseases that offers significantly less frequent dosing than current market leaders.